Home
Technology
Pipeline
Intranasal Naloxone
Intranasal Epinephrine
About us
Contact
News
Menu
Home
Technology
Pipeline
Intranasal Naloxone
Intranasal Epinephrine
About us
Contact
News
Nasus Pharma Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002 Intranasal Epinephrine
Click Here
Share this post
Previous
Nasus Pharma Announces Publication Of Its Positive Clinical Results With FMXIN002 Intranasal Powder Epinephrine Spray In The Journal Of Allergy And Clinical Immunology In Practice
Next
Nasus Pharma Announces Ground-Breaking Five Years Stability of its FMXIN002 Nasal Epinephrine Powder for Severe Allergy and Anaphylaxis
